Effectiveness and Safety of Recombinant Type <scp>III</scp> Humanized Collagen Solution Injection Combined With Collagen‐ <scp>III</scp> Multi‐Peptide Serum in Improving Signs of Photoaging: A Prospective, Split‐Face Controlled Clinical Trial

BACKGROUND: Skin aging is a multifactorial process involving the progressive deterioration of skin structure and function, marked by collagen degeneration, impairing the structural integrity of the dermis. Intradermal injection of recombinant type III humanized collagen (RhCol-III) solution is a promising anti-aging strategy through direct collagen replenishment, but its synergistic effects when combined with a collagen-III multi-peptide serum remain unexplored. AIMS: This study evaluates the effectiveness and safety of a RhCol-III solution injection combined with a collagen-III multi-peptide serum in improving photoaging. METHODS: A prospective, single-center, randomized, split-face, single-blind trial was conducted. Participants received an intradermal injection of 2 mg/mL RhCol-III solution with application of collagen-III multi-peptide serum on the test side and intradermal injection of RhCol-III solution only on the control side. The 12-week follow-up period assessed effectiveness and safety, with the primary endpoint being the participant-reported skin satisfaction score (FACE-Q satisfaction with skin) at 4 weeks post-treatment. RESULTS: A total of 54 participants were enrolled. The primary endpoint, FACE-Q skin satisfaction score at week 4, significantly improved on both tested and control sides by 40.0% vs. 34.8% from baseline (both p < 0.0001; p < 0.05 between sides). By week 12, the tested side showed significantly better outcomes versus the control side in FACE-Q skin satisfaction scores, GAIS significant improvement rates, improvement rates of fine lines and skin firmness (all p < 0.05). No adverse events related to the RhCol-III solution injection were observed. CONCLUSIONS: The combination of injectable RhCol-III and topical collagen-III multi-peptide serum is effective and safe in ameliorating photoaging of the forehead, periorbital and cheek areas among the Chinese population.

Authors

Institutions

Publication Details

Journal
Journal of Cosmetic Dermatology
Published
2026-05-01
DOI
https://doi.org/10.1111/jocd.70857
Primary Topic
Skin Protection and Aging
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Effectiveness and Safety of Recombinant Type III Humanized Collagen Solution Injection Combined With Collagen‐ III Multi‐Peptide Serum in Improving Signs of Photoaging: A Prospective, Split‐Face Controlled Clinical Trial

Lingyan Liu, Qi Shi, Lin Zhu, Yining Luo et al.
Journal of Cosmetic Dermatology
Skin Protection and Aging
article

Effectiveness and Safety of Recombinant Type III Humanized Collagen Solution Injection Combined With Collagen‐ III Multi‐Peptide Serum in Improving Signs of Photoaging: A Prospective, Split‐Face Controlled Clinical Trial

Lingyan Liu, Qi Shi, Lin Zhu, Yining Luo, Xiaolei Qin, Hong Shu, Jinlong Zhai
article en

Abstract

BACKGROUND: Skin aging is a multifactorial process involving the progressive deterioration of skin structure and function, marked by collagen degeneration, impairing the structural integrity of the dermis. Intradermal injection of recombinant type III humanized collagen (RhCol-III) solution is a promising anti-aging strategy through direct collagen replenishment, but its synergistic effects when combined with a collagen-III multi-peptide serum remain unexplored. AIMS: This study evaluates the effectiveness and safety of a RhCol-III solution injection combined with a collagen-III multi-peptide serum in improving photoaging. METHODS: A prospective, single-center, randomized, split-face, single-blind trial was conducted. Participants received an intradermal injection of 2 mg/mL RhCol-III solution with application of collagen-III multi-peptide serum on the test side and intradermal injection of RhCol-III solution only on the control side. The 12-week follow-up period assessed effectiveness and safety, with the primary endpoint being the participant-reported skin satisfaction score (FACE-Q satisfaction with skin) at 4 weeks post-treatment. RESULTS: A total of 54 participants were enrolled. The primary endpoint, FACE-Q skin satisfaction score at week 4, significantly improved on both tested and control sides by 40.0% vs. 34.8% from baseline (both p < 0.0001; p < 0.05 between sides). By week 12, the tested side showed significantly better outcomes versus the control side in FACE-Q skin satisfaction scores, GAIS significant improvement rates, improvement rates of fine lines and skin firmness (all p < 0.05). No adverse events related to the RhCol-III solution injection were observed. CONCLUSIONS: The combination of injectable RhCol-III and topical collagen-III multi-peptide serum is effective and safe in ameliorating photoaging of the forehead, periorbital and cheek areas among the Chinese population.

Journal of Cosmetic DermatologyVol. 25(5)
SKiN Health (CA)
Good health and well-being
Openalex Percentile: Top 9%
Skin Protection and Aging
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.